Toripalimab was Coherus Oncology’s largest product and service line in fiscal 2025, bringing in $40.84M of $42.17M (97%).
| Product and Service | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales Of Udenyca | — | — | — | — | ||||
| Udenyca | $203.81M | $127.06M | — | — | ||||
| Cimerli | $6.95M | $125.39M | — | — | ||||
| Toripalimab | — | — | $19.13M | $40.84M | ||||
| Toripalimab (Loqtorzi) | — | $554.00K | — | — | ||||
| Yusimry | — | $3.57M | — | — | ||||
| Other Revenue | $282.00K | $664.00K | $7.26M | $1.34M | ||||
| Other | — | — | — | — | ||||
| Collaboration & License Revenue | — | — | — | — | ||||
| Total | $211.04M | $257.24M | $26.39M | $42.17M |
Coherus Oncology brought in $42.17M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 59.8% from $26.39M in fiscal 2024. Toripalimab was the largest at $40.84M (96.8%), ahead of Other Revenue at $1.34M (3.2%).
Compared with fiscal 2024, Toripalimab grew 113.5% to $40.84M, while Other Revenue fell 81.6% to $1.34M.
Coherus Oncology began breaking out Toripalimab in fiscal 2024, when it brought in $19.13M. Coherus Oncology stopped reporting Udenyca ($127.06M in fiscal 2023), Cimerli ($125.39M in fiscal 2023), Yusimry ($3.57M in fiscal 2023) and one other as separate lines.
Coherus Oncology (CHRS) reports its revenue by product and service. In fiscal 2025, Toripalimab was its largest product and service line, bringing in $40.84M (96.8% of the total), followed by Other Revenue at $1.34M (3.2%).
Toripalimab was Coherus Oncology's largest product and service line in fiscal 2025, bringing in $40.84M, or 96.8% of the $42.17M total across its two product and service lines.
Toripalimab grew faster than Other Revenue in fiscal 2025, up 113.5% from $19.13M to $40.84M. Other Revenue fell 81.6% to $1.34M.
Every figure comes from Coherus Oncology's annual financial filings, as reported. Each line keeps the name Coherus Oncology gives it, and years follow its fiscal calendar.
Coherus Oncology's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.